Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare R...
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on latest market data analysis and mixed signs on the horizo... (8/1/2020)
   
Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare Reform and Cost Containment (8/1/2020)
China's Proposals to Provide a Patent Linkage System and Patent Term Extensions - Considerations for Drug Companies (7/29/2020)
China: Looking Back at 2019's Main IP Developments and Looking Forward At What 2020 May Bring (7/28/2020)
New Draft Patent Law - What To Expect and What Not to Expect (7/16/2020)
Long Awaited Chinese Civil Code - Impacts on IPR (7/14/2020)
China's Latest Patent Law Amendment Introduces Patent Linkage And Patent Term Extension (7/14/2020)
Revisiting the Basis of Your China Strategy in the Post-Covid New Normal (7/1/2020)
Trends in U.S. Multinational Enterprise Activity in China, 2000-2017 (7/1/2020)
Ex-USPTO Head, Retired Judge Back China Pharma IP Reform (6/30/2020)
How Data Protection Matters for Pharma Cos in Mainland China? - Ensuring Compliance and Mitigating Risk (6/30/2020)
In Depth: Decoding China's First Civil Code (6/23/2020)
Dealing with the Chinese Economy after COVID-19 (6/3/2020)
Chinese Antitrust Authority Imposes Maximum Fine In Rare Abuse Of Collective Dominance Case (6/1/2020)
Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain (6/1/2020)
Challenges Posed to Chinese Biotechs in Post-Pandemic Era (5/28/2020)
G1 Therapeutics and Simcere Enter Licens...  (8/3/2020)
NHSA Solicits Feedbacks on the 2020 NRDL...  (8/3/2020)
The CDE Solicits Comments on the Guidanc...  (8/3/2020)
The CDE Solicits Comments on the Technic...  (8/3/2020)
The CDE Solicits Comments on the Technic...  (8/3/2020)
The CDE Solicits Comments on the Technic...  (8/3/2020)
The CDE Solicits Comments on the Technic...  (8/3/2020)
The CDE Solicits Comments on the Guideli...  (8/3/2020)
NMPA Issues the Guidelines for Clinical ...  (8/3/2020)
NMPA Solicits Comments on the Rules of P...  (8/3/2020)
AstraZeneca's Q2 Growth Dragged Down by ...  (8/3/2020)
Sesen Bio and Qilu Pharma Enter License ...  (8/3/2020)
Pfizer's Topical Atopic Dermatitis Drug ...  (8/3/2020)
Review of Chinese Drug Evaluation and Re...  (8/1/2020)
NHSA Issues the Interim Measures for Adm...  (8/1/2020)
Pfizer to Absorb Mylan, Creating Global Generic Powerhou...
PhRMA Calls for Trade Deals That Force Countries to Pay ...
IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
Pfizer and GSK Announce JV to Create a Global Consumer H...
Top 25 Global Pharmaceutical Companies by Market Cap 201...
Nicholas Hall Reports 4.5% Growth for the Chinese OTC Analgesic...
IQVIA: Overall Chinese Pharma Market Growth Rebounded to 8.4% i...
China Oncology Drugs Market - Growth Opportunities Created by C...
Snapshot of Chinese Non-prescription Drug Market 2016-2019
IQVIA: Shanghai Drug Market Growth Up Substantially in 2019
G1 Therapeutics and Simcere Enter License Deal for Trilacicl...
AstraZeneca's Q2 Growth Dragged Down by China Decline
Sesen Bio and Qilu Pharma Enter License Deal for Vicineum in...
Pfizer's Topical Atopic Dermatitis Drug Eucrisa Approved in ...
Financial-related Company News in Brief
The CDE Solicits Comments on the Guidance Principles on ...
The CDE Solicits Comments on the Technical Guidelines fo...
The CDE Solicits Comments on the Technical Guidelines fo...
The CDE Solicits Comments on the Technical Guidelines fo...
The CDE Solicits Comments on the Technical Guidelines on...
NPC Solicits Comments on 2nd Draft of the Chinese Patent Law...
Punitive Damages in China's New Civil Code
SAMR Issues Notice to Strengthen Anti-Unfair Competition Enf...
Beijing Plans to Criminalize Criticisms of Traditional Chine...
NPC to Prioritize Legislation on Public Health in 2020
Fitch: No Near-Term Impact on Chinese API Makers as Phar...
Indian Firms Challenged by API Price Hikes by Chinese Su...
Snapshot of the Chinese API Sector
India to Boost API Output as Alternative Source to China...
India Lifts Export Restrictions on 24 APIs
Terns Announces Completion and Positive Results from Pha...
Gan & Lee Pharmaceuticals Initiates First-in Human P...
Chi-Med's NDA for Savolitinib in Non-Small Cell Lung Can...
BeiGene Announces Acceptance of NDA for Pamiparib in Ova...
Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibit...
NHSA Solicits Feedbacks on the 2020 NRDL Revision Work P...
NHSA Issues the Interim Measures for Administration of B...
NHC Issues Notice to Step Up Single Disease Group Qualit...
APO Issues Bidding Documents for the Third Batch of VBP
NHC Solicits Comments on the Rules for Clinical Applicat...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Senior Chinese Pharma Official Investigated for Serious Le...
Recent Executive Movements
USTR Satisfied with China's Implementatin of Phase 1 US-...
U.S.-China ESRC Hearing: China's Evolving Healthcare Sys...
AmCham Survey: Supply Chain Challenges for US Companies ...
Upcoming Event: 2nd World Congress on Dermatology and Ae...
Upcoming Event: XI International Exhibition of Equipment...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Publishes the China Phar...
  WiCON to Hold Pharma China Ann...
  WiCON Publishes the China Phar...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links